US2013041138A1PendingUtilityA1

Antibodies that bind to psca proteins for diagnosis of cancer

Assignee: GUDAS JEANPriority: May 30, 2003Filed: Sep 28, 2012Published: Feb 14, 2013
Est. expiryMay 30, 2023(expired)· nominal 20-yr term from priority
A61P 35/00A61P 43/00A61P 39/00G01N 33/57515A61K 51/1051C07K 16/30C07K 16/3069A61K 51/1057A61K 2039/53C07K 14/705C07K 14/4748A61K 51/1054A61K 51/106C07K 2317/73G01N 33/566A61K 51/1072A61K 40/4275A61K 40/24A61K 40/19A61K 2239/58Y02A50/30A61K 39/0011C07K 16/28C07K 7/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.

Claims

exact text as granted — not AI-modified
1 . A monoclonal antibody or antigen binding fragment thereof comprising an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody comprises the amino acid sequence of the V H  region of SEQ ID NO: 35 and the V L  region of SEQ ID NO: 37.

Join the waitlist — get patent alerts

Track US2013041138A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.